ST Tian Sheng: Wholly-owned subsidiary's Vitamin B6 injection has passed the consistency evaluation for generic drugs.

ST Tian Sheng announced that its wholly-owned subsidiary, Hubei Tian Sheng Pharmaceutical Co., Ltd., has recently received the "Approval Notification for Drug Supplement Application" issued by the National Medical Products Administration. The product "Vitamin B6 Injection" has passed the consistency evaluation of generic drugs. The specification of the drug is 1ml:0.1g, and the approval number is valid until March 28, 2027. It is clinically used for the prevention and treatment of Vitamin B6 deficiency, among other purposes. This evaluation success helps the company accumulate experience for future related work; however, drug sales are subject to policy and market environment influences, which entail uncertainty.